{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '15', 'CLINICAL TRIAL PROTOCOL AMENDMENTS', '98', '16', 'BIBLIOGRAPHIC REFERENCES', '99', '17', 'APPENDICES', '102', 'APPENDIX, A GUIDANCE ON CONTRACEPTIVE METHODS AND COLLECTION OF', 'PREGNANCY INFORMATION', '103', 'APPENDIX B GENERAL GUIDANCE FOR THE FOLLOW-UP OF LABORATORY', 'ABNORMALITIES BY SANOFI', '105', \"APPENDIX C MC DONALD'S CRITERIA FOR DIAGNOSIS OF MS\", '113', \"APPENDIX D KURTZKE'S FUNCTIONAL SYSTEMS AND EXPANDED DISABILITY STATUS\", 'SCALE IN MULTIPLE SCLEROSIS', '114', 'APPENDIX E TANNER STAGE CLASSIFICATION', '124', 'APPENDIX F 23-ITEM PEDSQL GENERIC CORE SCALES', '125', 'APPENDIX G NEUROQOL', '133', 'APPENDIX H COUNTRY-SPECIFIC REQUIREMENTS', '138', 'APPENDIX I PROTOCOL AMENDMENT HISTORY', '141', 'Property of the Sanofi Group - strictly confidential', 'Page 27', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '2.1', 'LIST OF TABLES', 'Table 1 - Schedule of events in Year 1', '14', 'Table 2 - Schedule of events in Year 2', '17', 'Table 3 - Safety monitoring phase Year 3-5', '19', 'Table 4 - PK Sampling schedule (Year 1)', '21', 'Table 5 - PK sampling schedule (Year 2)', '21', 'Table 6 - MRI correlative analyses with relapse in adult Phase 3 studies (CAMMS323 and CAMMS324) 32', 'Table 7 - Common terminology criteria for adverse events v3.0, published 09 August 2006', '45', 'Table 8 - List of pharmacokinetic parameters and definitions', '57', 'Table 9 - Summary of adverse event reporting instructions', '82', 'Property of the Sanofi Group - strictly confidential', 'Page 28', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '3', 'LIST OF ABBREVIATIONS', 'ADA:', 'antidrug antibody', 'AE:', 'adverse event', 'ALT:', 'alanine aminotransferase', 'ARR:', 'annualized relapse rate', 'AUC:', 'area under the cumulative serum concentration versus time curve', 'AUClast:', 'area under the cumulative serum concentration versus time curve extrapolated to', 'infinity', 'BVMT-R:', 'Brief Visuospatial Memory Test-Revised', 'CBC:', 'complete blood count', 'Cmax:', 'maximum serum concentration observed', 'CMV:', 'cytomegalovirus', 'CTCAE:', 'Common Terminology Criteria for Adverse Events', 'DMC:', 'Data Monitoring Committee', 'DMT:', 'disease modifying therapy', 'e-CRF:', 'electronic-case report form', 'EDSS:', 'Expanded Disability Status Scale', 'EMA:', 'European Medicines Agency', 'EOS:', 'end of safety monitoring phase', 'EOTP:', 'end of treatment phase', 'EU:', 'European Union', 'GA:', 'glatiramer acetate', 'GBM:', 'glomerular basement membrane', 'GCP:', 'Good Clinical Practice', 'Gd:', 'gadolinium', 'GEE:', 'generalized estimating equations', 'H1:', 'histamine receptor H1', 'H2:', 'histamine receptor H2', 'HLGT:', 'high level group term', 'HLH:', 'hemophagocytic lymphohistiocytosis', 'HLT:', 'high level term', 'HPV:', 'human papillomavirus', 'HSV:', 'herpes simplex virus', 'IAR:', 'infusion-associated reaction', 'ICF:', 'informed consent form', 'IEC:', 'independent ethics committee', 'IFNB:', 'interferon beta', 'IFNB-1a:', 'interferon beta 1-alpha', 'IMP:', 'Investigational Medicinal Product', 'IRB:', 'institutional review board', 'ITP:', 'immune thrombocytopenia', 'IV:', 'intravenous(ly)', 'IVRS:', 'interactive voice response system', 'Property of the Sanofi Group - strictly confidential', 'Page 29', 'VV-CLIN-0254406 5.0']\n\n###\n\n", "completion": "END"}